Related Experiment Video

Updated: Jul 5, 2025

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

9.2K

FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and

Daiki Kanaoka1, Mitsuo Yamada1, Hironori Yokoyama1

  • 1Department of Scientific Research, Fujimoto Pharmaceutical Corporation, Nishi-otsuka, Matsubara, Osaka, Japan.

Cancer Research Communications
|January 24, 2024
PubMed

Insights

The novel compound FPFT-2216 effectively degrades casein kinase 1α (CK1α), inhibiting lymphoma cell growth by activating p53 signaling and suppressing the CBM/NFκB pathway. This offers a promising new therapeutic strategy for hematopoietic malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Casein kinase 1α (CK1α) expression reduction inhibits cancer cell growth, identifying it as a potential therapeutic target.
  • Lymphoid tumors and hematopoietic malignancies represent significant clinical challenges, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the antitumor activity of the novel compound FPFT-2216 in lymphoid tumors.
  • To elucidate the molecular mechanism of action of FPFT-2216, focusing on CK1α degradation.
  • To assess the potential of FPFT-2216 in treating hematopoietic malignancies.

Main Methods:

  • In vitro and in vivo studies using lymphoma cell lines and xenograft models.
  • Assessment of protein degradation via proteasomal pathways (CK1α, IKZF1/3).
  • Analysis of signaling pathways including p53, p21, MDM2, CBM complex, IκBα, and NFκB phosphorylation.

Main Results:

  • FPFT-2216 strongly degraded CK1α and IKZF1/3 via proteasomal degradation.
  • FPFT-2216 demonstrated superior inhibition of lymphoma cell proliferation compared to thalidomide derivatives, inducing p53 upregulation.
  • Combination therapy with an MDM2 inhibitor showed synergistic effects, leading to rapid tumor regression in vivo.
  • FPFT-2216 enhanced rituximab activity and showed efficacy in a patient-derived diffuse large B-cell lymphoma model.
  • FPFT-2216 inhibited CBM complex activity and NFκB phosphorylation, mediated by CK1α degradation.

Conclusions:

  • FPFT-2216 exhibits potent antitumor activity by activating p53 signaling and inhibiting the CBM complex/NFκB pathway through CK1α degradation.
  • FPFT-2216 demonstrates therapeutic potential for hematopoietic malignancies, including lymphoma, particularly in cases refractory to other treatments.
  • Targeting CK1α with FPFT-2216 represents a promising strategy for lymphoma treatment, offering advantages over existing therapies.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

418
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

942

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K